Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
Madrigal Pharmaceuticals(MDGL) Newsfilter·2025-01-13 11:45Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectivelyPreliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 millionAs of year-end 2024, more than 11,800 patients on RezdiffraMadrigal to present at the 43rd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. PST (5:15 p.m. EST) on Wednesday January 15, 2025 CONSHOHOCKEN, Pa., Jan. 13, 20 ...